Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds

被引:28
作者
Figueiredo, Sandra A. C. [1 ,2 ]
Salvador, Jorge A. R. [1 ,2 ]
Cortes, Roldan [3 ]
Cascante, Marta [3 ]
机构
[1] Univ Coimbra, Lab Pharmaceut Chem, Fac Pharm, P-3000548 Coimbra, Portugal
[2] Ctr Neurosci & Cell Biol, Coimbra, Portugal
[3] Univ Barcelona, Dept Biochem & Mol Biomed, Fac Biol, Inst Biomed, Diagonal 643, E-08028 Barcelona, Spain
关键词
Celastrol; Triterpenes; Carbamates; Cytotoxicity; Apoptosis; Drug synergy; ANTITUMOR-ACTIVITY; CANCER-CELLS; ASIATIC ACID; ANTICANCER; CARBOPLATIN; HSP90-CDC37; INHIBITION; PACLITAXEL; MECHANISM; MOIETY;
D O I
10.1016/j.ejmech.2017.08.058
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Celastrol and its derivatives have been reported for their potent anticancer activity. Among other celastrol analogues, novel carbamate derivatives were designed and synthesised, and their biological activity on the viability of human cancer cell lines was evaluated. Additionally, a preliminary structure activity relationship study was conducted. Derivative 18 showed the highest activity on cancer cell viability, combined with the best selectivity between malignant cells and non-malignant fibroblasts. Preliminary mechanistic studies of its anti-tumour action indicated that compound 18 has an anti proliferative effect on SKOV-3 human ovarian cancer cells (IC50 = 0.54 mu M). The results also suggested that its potent anticancer activity is mediated by apoptosis, and that this process was mainly the result of the activation of the extrinsic apoptotic pathway. Moreover, our results demonstrated the potential of derivative 18 as a new agent for combinatorial drug therapy for ovarian cancer. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:836 / 848
页数:13
相关论文
共 50 条
[21]   Remarkable Stereospecific Conjugate Additions to the Hsp90 Inhibitor Celastrol [J].
Klaic, Lada ;
Trippier, Paul C. ;
Mishra, Rama K. ;
Morimoto, Richard I. ;
Silverman, Richard B. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, 133 (49) :19634-19637
[22]  
Lee Byong Won, 2004, Journal of Applied Biological Chemistry, V47, P77
[23]   The Main Anticancer Bullets of the Chinese Medicinal Herb, Thunder God Vine [J].
Liu, Zi ;
Ma, Liang ;
Zhou, Guang-Biao .
MOLECULES, 2011, 16 (06) :5283-5297
[24]   Anti-inflammatory and immuno suppressive compounds from Tripterygium wilfordii [J].
Ma, Jun ;
Dey, Moul ;
Yang, Hui ;
Poulev, Alexander ;
Pouleva, Reneta ;
Dorn, Ruth ;
Lipsky, Peter E. ;
Kennelly, Edward J. ;
Raskin, Ilya .
PHYTOCHEMISTRY, 2007, 68 (08) :1172-1178
[25]   Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum [J].
Markman, M ;
Kennedy, A ;
Webster, K ;
Peterson, G ;
Kulp, B ;
Belinson, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1901-1905
[26]   Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells [J].
Mendes, Vanessa I. S. ;
Bartholomeusz, Geoffrey A. ;
Ayres, Mary ;
Gandhi, Varsha ;
Salvador, Jorge A. R. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 123 :317-331
[27]   Novel oleanolic vinyl boronates: Synthesis and antitumor activity [J].
Moreira, Vania M. ;
Salvador, Jorge A. R. ;
Simoes, Sergio ;
Destro, Federica ;
Gavioli, Riccardo .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 63 :46-56
[28]  
Morgan D M, 1998, Methods Mol Biol, V79, P179
[29]   Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer [J].
Neijt, JP ;
Engelholm, SA ;
Tuxen, MK ;
Sorensen, PG ;
Hansen, M ;
Sessa, C ;
de Swart, CAM ;
Hirsch, FR ;
Lund, B ;
van Houwelingen, HC .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3084-3092
[30]   Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide [J].
Quinney, SK ;
Sanghani, SP ;
Davis, WI ;
Hurley, TD ;
Sun, Z ;
Murry, DJ ;
Bosron, WF .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :1011-1016